气动腿部压缩对费尼莱弗林剂量对低血压预防的作用通过剖腹产时的可变速率输液:一个未盲目的随机对照试验
H Q Yao1, J Y Huang1, Y F Dong1
1Department of Anesthesiology, Jiaxing Maternity and Children Health Care Hospital, Affiliated Women and Children Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
International journal of obstetric anesthesia
|June 26, 2024
概括
将间歇性气压压缩 (IPC) 添加到利弗林输注中,显著降低了每分钟所需的利弗林剂量和剖腹产期间低血压的发生率. 这种组合提供了一种更安全的方法来管理脊柱麻醉期间的血压.
科学领域:
- 麻醉学 麻醉学
- 产科 产科 产科 产科 产科
- 心血管生理学心血管生理学
背景情况:
- 烯输注是预防剖腹产期间脊柱低血压的标准.
- 然而,使用乙烯可以导致剂量依赖的副作用.
- 这项研究研究了一种方法来降低CD.期间的烯剂量.
研究的目的:
- 为了确定下肢间歇性气动压缩 (IPC) 是否降低了剖腹产期间所需的烯剂量.
- 评估IPC对CD期间低血压发生率的影响.
主要方法:
- 在脊髓麻醉下接受选择性CD的76名妇女被随机分配到IPC或对照组.
- 在干预组中,IPC应用于下腿.
- 进行了可变速率的烯输液,用于重度低血压,主要结局是每分钟的烯剂量.
主要成果:
- IPC组每分钟需要的烯显著减少 (34.4比40.9μg·min-1,P=0.001).
- 在IPC组中,低血压的发生率较低 (24%对55%,P=0.005).
- 没有观察到烯总剂量,孕产妇副作用或新生儿结局的显著差异.
结论:
- 将间歇性气压压缩与可变速率的利注入相结合,可以有效地降低剖腹产期间每分钟的利剂量.
- 这一策略还降低了接受CD脊髓麻醉的患者中低血压的发生率.
相关概念视频
Local Anesthetics: Clinical Application as Epidural Anesthesia
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


